

11/30/99
JC674 U.S. PTO

Attorney Docket No.: 5739.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL021370267US
Date of Deposit November 30, 1999
Sir:

JC678 U.S. PTO
09/450609
11/30/99

This is a request for filing an application under 37 C.F.R. 1.53(b) of
Applicant(s): Weibel et al.

Title: New Pharmaceutical Composition And The Process For Its Preparation

16 pages of specification 0 sheets of drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$760.00
Total Claims: $19 - 20 = 0 \times 18 =$	\$0
Independent Claims: $2 - 3 = 0 \times 78 =$	\$0
Total Fee:	\$760.00

Priority of Danish application no. PA 1998 01580 filed on December 1, 1998 is
claimed under 35 U.S.C. 119. A certified copy is submitted herewith.

Priority of U.S. provisional application no. 60/112,248 filed on December 14, 1998
is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: New Pharmaceutical Composition And The Process For Its
Preparation
Applicants: Weibel et al.

Sir:

Express Mail Label No. EL021370267US

Date of Deposit : November 30, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Certified Copy of Priority Application

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Gina Maldonado

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123